<DOC>
	<DOCNO>NCT00040014</DOCNO>
	<brief_summary>The purpose study find two different formulation exemestane ( Aromasin ) , oral injectable , equivalent term pharmacodynamics pharmacokinetics , i.e. , ultimately formulation efficacy postmenopausal woman metastatic breast cancer fail previous antiestrogens therapy equally safe .</brief_summary>
	<brief_title>Open Label , Multicenter , Randomized , Controlled Study IM Oral Exemestane ( Aromasin ) Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>diagnose breast cancer estrogen receptor positivity Postmenopausal status advance disease progression previous tamoxifen therapy 1 chemotherapy / 1 hormonotherapy advance disease previous hormonotherapy Tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>